Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Coal tar 12% / Salicylic acid 2% in Emulsifying ointment
1305020C0AAEGEG
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 12% in Yellow soft paraffin
1305020C0AAGTGT
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 12%/Salicylic acid 2% in Hydrocortisone 1%
1305020I0AAAKAK
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar 15% in Betamethasone valerate 0.025% ointment
1304000F0AAEYEY
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 2% / Salic acid 2% / Sulfur 2% in Gen Unguen M crm
1305020C0AAHBHB
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 2% in Aqueous cream
1305020C0AAGXGX
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 2% in Betamethasone dipropionate 0.05% ointment
1304000D0AACECE
|
Betamethasone esters | Betamethasone esters | Skin | No data available |
|
Coal tar 2% in Betamethasone valerate 0.1% cream
1304000F0AAFAFA
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 2% in Betamethasone valerate 0.1% ointment
1304000F0AAFBFB
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 2% in Emulsifying ointment
1305020C0AAGFGF
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 2% in White soft paraffin
1305020C0AAGGGG
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 2%/Salicylic acid 3% in Betamethasone valerate 0.1%
1305020I0AAALAL
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar 20% in White soft paraffin
1305020C0AAHEHE
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 3% / Salicylic acid 2% in Aqueous cream
1305020C0AAFKFK
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 3% / Salicylic acid 2% in Clobetasol 0.05% ointment
1304000G0AACUCU
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar 3% / Salicylic acid 3% in Aqueous cream
1305020C0AAEBEB
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 30% in Yellow soft paraffin
1305020C0AAHCHC
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 4.3% shampoo
1309000C0AAASAS
|
Coal tar (Scalp) | Coal tar | Skin | No data available |
|
Coal tar 5% / Salicylic acid 2% in Betameth val 0.025% oint
1304000F0AAEFEF
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 5% / Salicylic acid 2% in Emulsifying ointment
1305020C0AAEMEM
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 5% / Salicylic acid 3% in Emulsifying ointment
1305020C0AAGRGR
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 5% / Salicylic acid 5% in Emulsifying ointment
1305020C0AAHHHH
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 5% in Betamethasone dipropionate 0.05% ointment
1304000D0AACFCF
|
Betamethasone esters | Betamethasone esters | Skin | No data available |
|
Coal tar 5% in Betamethasone valerate 0.1% ointment
1304000F0AAEWEW
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 5% in Clobetasone 0.05% cream
1304000H0AACWCW
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.